Memphasys (MEM) Stock Overview
Develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
MEM Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Memphasys Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.0035 |
| 52 Week High | AU$0.011 |
| 52 Week Low | AU$0.003 |
| Beta | 0.40 |
| 1 Month Change | -12.50% |
| 3 Month Change | -30.00% |
| 1 Year Change | -61.11% |
| 3 Year Change | -84.09% |
| 5 Year Change | -96.96% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Is Memphasys (ASX:MEM) A Risky Investment?
Sep 03
Here's Why Memphasys (ASX:MEM) Can Afford Some Debt
Mar 02Is Memphasys (ASX:MEM) Using Too Much Debt?
Jun 19Memphasys (ASX:MEM) Is Making Moderate Use Of Debt
Mar 01Memphasys (ASX:MEM) Is Making Moderate Use Of Debt
Jun 13Does Memphasys (ASX:MEM) Have A Healthy Balance Sheet?
Jun 20Is Memphasys (ASX:MEM) A Risky Investment?
Feb 28Memphasys (ASX:MEM) Is Making Moderate Use Of Debt
Sep 01Will Memphasys (ASX:MEM) Spend Its Cash Wisely?
Jan 07Shareholder Returns
| MEM | AU Life Sciences | AU Market | |
|---|---|---|---|
| 7D | -12.5% | -3.0% | -1.1% |
| 1Y | -61.1% | -45.2% | 10.9% |
Return vs Industry: MEM underperformed the Australian Life Sciences industry which returned -44.5% over the past year.
Return vs Market: MEM underperformed the Australian Market which returned 10.7% over the past year.
Price Volatility
| MEM volatility | |
|---|---|
| MEM Average Weekly Movement | 31.8% |
| Life Sciences Industry Average Movement | 9.0% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in AU Market | 19.4% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: MEM's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: MEM's weekly volatility has increased from 26% to 32% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | n/a | David Ali | www.memphasys.com |
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company primarily develops Felix, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, a rapid oxidative stress assay; and AI-Port.
Memphasys Limited Fundamentals Summary
| MEM fundamental statistics | |
|---|---|
| Market cap | AU$6.94m |
| Earnings (TTM) | -AU$4.94m |
| Revenue (TTM) | AU$526.92k |
Is MEM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MEM income statement (TTM) | |
|---|---|
| Revenue | AU$526.92k |
| Cost of Revenue | AU$95.86k |
| Gross Profit | AU$431.06k |
| Other Expenses | AU$5.37m |
| Earnings | -AU$4.94m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0025 |
| Gross Margin | 81.81% |
| Net Profit Margin | -937.89% |
| Debt/Equity Ratio | 88.8% |
How did MEM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/05 18:13 |
| End of Day Share Price | 2025/09/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Memphasys Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.